Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 71

1.

Linagliptin but not Sitagliptin inhibited transforming growth factor-β2-induced endothelial DPP-4 activity and the endothelial-mesenchymal transition.

Shi S, Kanasaki K, Koya D.

Biochem Biophys Res Commun. 2016 Jan 27. pii: S0006-291X(16)30154-1. doi: 10.1016/j.bbrc.2016.01.154. [Epub ahead of print]

2.

Concerted efforts to combat diabetic complications.

Kanasaki K.

Kidney Int. 2016 Feb;89(2):269-71. doi: 10.1016/j.kint.2015.12.023.

PMID:
26806828
3.

[Kidney fibrosis and endothelial injury].

Kanasaki K.

Nihon Jinzo Gakkai Shi. 2015;57(7):1200-5. Japanese. No abstract available.

PMID:
26665611
4.

The relevance of the Renin-Angiotensin system in the development of drugs to combat preeclampsia.

Ueki N, Takeda S, Koya D, Kanasaki K.

Int J Endocrinol. 2015;2015:572713. doi: 10.1155/2015/572713. Epub 2015 Apr 27. Review.

5.

Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition.

Shi S, Srivastava SP, Kanasaki M, He J, Kitada M, Nagai T, Nitta K, Takagi S, Kanasaki K, Koya D.

Kidney Int. 2015 Sep;88(3):479-89. doi: 10.1038/ki.2015.103. Epub 2015 Apr 1.

PMID:
25830763
6.

Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial.

Kato S, Maruyama S, Makino H, Wada J, Ogawa D, Uzu T, Araki H, Koya D, Kanasaki K, Oiso Y, Goto M, Nishiyama A, Kobori H, Imai E, Ando M, Matsuo S.

Clin Exp Nephrol. 2015 Dec;19(6):1098-106. doi: 10.1007/s10157-015-1106-2. Epub 2015 Mar 21.

7.

Combating kidney fibrosis.

Kanasaki K, Maeshima A, Taduri G, Revuelta I.

Biomed Res Int. 2014;2014:679154. doi: 10.1155/2014/679154. Epub 2014 Sep 7. No abstract available.

8.

Lipid mediators in diabetic nephropathy.

Srivastava SP, Shi S, Koya D, Kanasaki K.

Fibrogenesis Tissue Repair. 2014 Sep 3;7:12. doi: 10.1186/1755-1536-7-12. eCollection 2014. Review.

9.

The role of ubiquitination and sumoylation in diabetic nephropathy.

Gao C, Huang W, Kanasaki K, Xu Y.

Biomed Res Int. 2014;2014:160692. doi: 10.1155/2014/160692. Epub 2014 Jun 4. Review.

10.

Low-protein diet for diabetic nephropathy.

Otoda T, Kanasaki K, Koya D.

Curr Diab Rep. 2014;14(9):523. doi: 10.1007/s11892-014-0523-z. Review.

PMID:
24986448
11.

The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis.

Nagai T, Nitta K, Kanasaki M, Koya D, Kanasaki K.

Clin Exp Nephrol. 2015 Feb;19(1):65-74. doi: 10.1007/s10157-014-1000-3. Epub 2014 Jul 1. Review.

PMID:
24975544
12.

Clinical therapeutic strategies for early stage of diabetic kidney disease.

Kitada M, Kanasaki K, Koya D.

World J Diabetes. 2014 Jun 15;5(3):342-56. doi: 10.4239/wjd.v5.i3.342. Review.

13.

Cancer biology in diabetes.

Sen S, He Y, Koya D, Kanasaki K.

J Diabetes Investig. 2014 May 4;5(3):251-64. doi: 10.1111/jdi.12208. Epub 2014 Mar 5. Review.

14.

Three ileus cases associated with the use of dipeptidyl peptidase-4 inhibitors in diabetic patients.

Kanasaki K, Konishi K, Hayashi R, Shiroeda H, Nomura T, Nakagawa A, Nagai T, Takeda-Watanabe A, Ito H, Tsuda S, Kitada M, Fujii M, Kanasaki M, Nishizawa M, Nakano Y, Tomita Y, Ueda N, Kosaka T, Koya D.

J Diabetes Investig. 2013 Nov 27;4(6):673-5. doi: 10.1111/jdi.12095. Epub 2013 May 8.

15.

N-acetyl-seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition.

Nagai T, Kanasaki M, Srivastava SP, Nakamura Y, Ishigaki Y, Kitada M, Shi S, Kanasaki K, Koya D.

Biomed Res Int. 2014;2014:696475. doi: 10.1155/2014/696475. Epub 2014 Mar 24.

16.

N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes.

Kanasaki K, Nagai T, Nitta K, Kitada M, Koya D.

Front Pharmacol. 2014 Apr 14;5:70. doi: 10.3389/fphar.2014.00070. eCollection 2014. Review.

17.

Specific activation of K-RasG12D allele in the bladder urothelium results in lung alveolar and vascular defects.

Ayala de la Peña F, Kanasaki K, Kanasaki M, Vong S, Rovira C, Kalluri R.

PLoS One. 2014 Apr 23;9(4):e95888. doi: 10.1371/journal.pone.0095888. eCollection 2014.

18.

Combat diabetic nephropathy: from pathogenesis to treatment.

Gohda T, Mima A, Moon JY, Kanasaki K.

J Diabetes Res. 2014;2014:207140. doi: 10.1155/2014/207140. Epub 2014 Mar 11. No abstract available.

19.

Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen.

Kanasaki K, Shi S, Kanasaki M, He J, Nagai T, Nakamura Y, Ishigaki Y, Kitada M, Srivastava SP, Koya D.

Diabetes. 2014 Jun;63(6):2120-31. doi: 10.2337/db13-1029. Epub 2014 Feb 26.

20.

Interventions against nutrient-sensing pathways represent an emerging new therapeutic approach for diabetic nephropathy.

Koya D, Kitada M, Kume S, Kanasaki K.

Clin Exp Nephrol. 2014 Apr;18(2):210-3. doi: 10.1007/s10157-013-0908-3. Epub 2013 Nov 14. Review.

PMID:
24221306
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk